E.g., 03/29/2024
E.g., 03/29/2024
Title Category Credit Event date Price
Advanced Practice Provider Core Curriculum: Benign Prostatic Hyperplasia (2023)
    • 2.75 AMA PRA Category 1 Credit™
    • 2.75 Non-Physician Participation
$0.00 Member only benefit! Results of a recent survey sent to US based practicing urologists show that there has been an increase in the number of advanced practice providers (APPs) actively providing front-line urologic care. Based on these findings, it was determined that the AUA develop a modular curriculum to be used in advancing the standard of urologic education for APPs. This educational curriculum, developed in partnership with the Cleveland Clinic, is comprised of online videos targeted towards the most common reasons patients seek non-operative urologic care.
Advancing Gender Equity in Urology: Allyship for Men and Advocacy for Women Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There is a lack of widespread awareness of how gender bias or sexism affects women in the urological workplace, and while primarily women are contributing to the scientific literature that examines these issues, its dissemination to those in leadership or in charge of policy can be limited. Addressing this requires both advocacy from women and allyship from men to promote fair and equitable work environments.
AUA Guidelines on Advanced Prostate Cancer Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Incorporating the most updated AUA/ASTRO/SUO APC Guidelines, this course will be comprehensive in the approach to the diagnosis, management and outcomes of men with advanced, metastatic hormone sensitive prostate cancer (mHSPC) and castration-resistant prostate cancer (CRPC). The course will include germline testing, PSMA positron emission tomography imaging, and the use of androgen deprivation therapy in combination with novel androgen axis therapy and chemotherapy in men with newly diagnosed metastatic hormone-sensitive prostate cancer.
Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Review of advanced and metastatic prostate, bladder and kidney cancer. Most recent treatment guidelines are reviewed along with the studies that support them. Different disease spaces in oncologic care are discussed, including the medications used to treat them, their mechanism, side effects and efficacy. Role of the advanced practice provider is discussed for each tumor type. Finally, cases are presented along with management options for audience participationACKNOWLEDGEMENTSIndependent educational grant support provided by:
Contemporary Pharmacotherapy for OAB 2023: Monotherapy and Combined Pharmacotherapy to Optimize Treatment Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation.
Diversity, Equity and Inclusion in Urology: What Do We Need to Know Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 The course will review the statistics of underrepresented Blacks and Latinos in urology. Diversity, equity and inclusion initiatives are necessary for the advancement of urology. We will also include the LGBTQ population with respect to diversifying the urology workforce and identifying specific patient needs for the LGBTQ population. We will define the different types of racism and educate participants on the definition of racial and gender-based microaggression. We will identify tactics to address microaggressions in medicine.
Genetics and Genomics of GU Malignancies: Applications into Your Clinical Practice Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This case-based interactive course reviews the role of germline genetics in genitourinary (GU) cancers and how the identification of an alteration may impact precision oncology. We will provide a concise and comprehensive review of hereditary cancer genetics, and discuss genetic risk assessment, diagnosis and treatment for a range of hereditary kidney, urothelial carcinoma, prostate, and adrenal cancer syndromes. We will review current National Comprehensive Cancer Network® Guidelines for genetic evaluation of patients with kidney, upper tract, prostate, and adrenal cancers.
How to use PSMA-PET/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 he learners will understand the following critical clinical aspects with regard to the clinical application of prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)/CT scanning mode of action of PSMA-PET/CT: pitfalls of PSMA-PET/CT diagnostic accuracy depending on PSA, PSA double time, prostate cancer histology, application of PSMA-PET/CT to identify patients with intrapelvic nodal relapse who will benefit from local therapy such as salvage lymphadenectomy or stereotactic radiation therapy, application of PSMA-PET/CT to identify patients with organ-confined radiorecur
Live from AUA2023: Highlights in BPH
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 Live from AUA2023: Highlights in BPH is a panel discussion filmed during the 2023 AUA Annual Meeting!This activity is designed to increase the urologist’s understanding of how to translate the latest scientific advances into their routine clinical practice, improving the care of patients with BPH.
Managing Toxicities of Checkpoint Inhibitors: A Urologist’s Guide Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Checkpoint inhibitors (CPIs) are increasingly being utilized in the treatment of urinary tract cancers, with several approvals in metastatic and now nonmetastatic spaces in bladder, kidney and prostate cancer. Urologists are encountering many patients on these therapies and have even started their own infusion programs with immuno -oncology drugs. This course will discuss and provide a structured, case-based approach to managing toxicities from CPIs within a busy urological practice.
Prostate Cancer Diagnosis: AUA Guidelines on Use of PSA Biomarkers, MRI and Biopsy Techniques Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Prostate cancer detection remains one of the most common and most controversial aspects of urological practice. In addition to the complexities around screening and use of PSA, the role of other biomarkers, biopsy techniques such as transperineal biopsy and MRI for targeted biopsy are evolving rapidly. This course is intended for urologists, advanced practice providers and trainees interested in using the most evidence-based methods for optimizing detection of clinically important prostate cancers, while improving patient experience and minimizing complications.
Refractory Overactive Bladder: How to Select 3rd Line Therapies and Optimize Outcomes Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Upon completion, participants will be familiar with third-line therapies available to treat refractory overactive bladder (OAB), including the pros and cons of each option, the current data regarding outcomes to facilitate proper patient counseling and optimal techniques to maximize the success of the various therapies. The case-based format will provide real-world scenarios by which to learn about the implementation of successful third-line options.
The Changing Face of Advanced Prostate Cancer Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This is an ongoing course on advanced prostate cancer at the AUA Annual Meeting since 2012, and the changes over the last decade have been nothing less than breathtaking! In the early years, it was all about metastatic castrate-resistant prostate cancer (CRPC) with multiple new therapeutic advances starting in 2010, followed by abiraterone and enzalutamide and a focus on bone-targeted agents.
Update Series (2015) Lesson 11: Prostatic Gizmos and Treatments for BPH: Past, Present and Future $0.00 For the most timely topics and latest surgical techniques in urology, you won’t want to miss the 2015 AUA Update Series—the AUA’s most popular self-study CME product.All new topics for 2015!
Update Series (2015) Lesson 12: Female Urinary Incontinence: The Value and Challenges of Randomized Controlled Trials $0.00 For the most timely topics and latest surgical techniques in urology, you won’t want to miss the 2015 AUA Update Series—the AUA’s most popular self-study CME product.All new topics for 2015!

Pages